ACEL Financial Facts
State tax expense (benefit): 0Total operating expenses: 209.11K
See Full Income Statement
Accrued expenses: 225.49K
Total Stockholders' deficiency: -6.62M
See Full Balance Sheet
Tamir Biotechnology, Inc. (ACEL) Earnings
|
Expand Research on ACEL
| Next EPS Date | 8/5/26 *Est. | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -46.2% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +1.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/11/26  |
Q126 | N/A | $0.20 | N/A | N/A | $337.83M | N/A | N/A | N/A | ||
| 3/3/26 | Q425 | $0.00 | N/A | N/A | $341.45M | $335.27M | N/A |  | | Details | |
| 11/4/25 | Q325 | $0.16 | $0.21 | -$0.05 | $329.7M | $327.95M | N/A | | | Details | |
| 8/5/25 | Q225 | $0.08 | $0.21 | -$0.13 | $335.9M | $328.85M | N/A | | | Details | |
| 5/5/25 | Q125 | $0.17 | $0.24 | -$0.07 | $323.9M | $310.34M | N/A | | | Details | |
| 2/27/25 |
Q424 | N/A | $0.20 | N/A | N/A | $304.11M | N/A | N/A | N/A | ||
| 10/30/24 | Q324 | $0.06 | $0.20 | -$0.14 | $302.22M | $297.03M | N/A | | | Details | |
| 7/30/24 | Q224 | $0.17 | $0.21 | -$0.04 | $309.41M | $301.33M | N/A | | | Details |
